Cited 15 times in
Physiological and pathological changes of plasma urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor levels in healthy females and breast cancer patients
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 노재경 | - |
dc.contributor.author | 라선영 | - |
dc.contributor.author | 유내춘 | - |
dc.contributor.author | 정현철 | - |
dc.date.accessioned | 2020-07-02T17:15:31Z | - |
dc.date.available | 2020-07-02T17:15:31Z | - |
dc.date.issued | 1998 | - |
dc.identifier.issn | 0167-6806 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/176699 | - |
dc.description.abstract | The plasma urokinase-type plasminogen activator (uPA), plasminogen activator inhibitor-1 (PAI-1), and urokinase-type plasminogen activator receptor (uPAR) levels were measured in healthy volunteers and breast cancer patients. In pre-menopause healthy females, blood was sampled weekly during one menstruation cycle and menstruation phases (follicular, ovulatory, luteal) were determined by FSH/LH levels. uPA, PAI-1, and uPAR levels were at the nadir during ovulatory phase. uPA level was highest at follicular phase while PAI-1 level was highest at luteal phase. In comparison between pre- and post-menopause states, uPA and uPAR levels were higher in post-menopause state while PAI-1 level was higher in pre-menopause state. In breast cancer patients, uPA, PAI-1, and uPAR positive rates were low when we use the menopause-state-unmatched cut-off points. As we adjusted the cut-off points by menopause states, the PAI-1 positivity increased mainly in post-menopause cancer patients. These findings suggest that there is a minor but possible sequential change of these molecules during menstruation cycle which might blur the pathological positivity in pre-menopause cancer patients. The pathological elevation of PAI-1 was well detected in post-menopause cancer patients, but this elevation did not correlate with tumor burden such as number of metastatic sites or metastatic location. In conclusion, adjustment of physiological changes of uPA, PAI-1, and uPAR is required in determining pathological elevation of the plasma levels in cancer patients, especially in females. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Kluwer Academic | - |
dc.relation.isPartOf | BREAST CANCER RESEARCH AND TREATMENT | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Breast Neoplasms/blood* | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Menstrual Cycle/blood | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Plasminogen Activator Inhibitor 1/blood* | - |
dc.subject.MESH | Receptors, Cell Surface/blood* | - |
dc.subject.MESH | Receptors, Urokinase Plasminogen Activator | - |
dc.subject.MESH | Urokinase-Type Plasminogen Activator/blood* | - |
dc.title | Physiological and pathological changes of plasma urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor levels in healthy females and breast cancer patients | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Hyun Cheol Chung | - |
dc.contributor.googleauthor | Sun Young Rha | - |
dc.contributor.googleauthor | Joon Oh Park | - |
dc.contributor.googleauthor | Nae Choon Yoo | - |
dc.contributor.googleauthor | Joo Hang Kim | - |
dc.contributor.googleauthor | Jae Kyung Roh | - |
dc.contributor.googleauthor | Jin Sik Min | - |
dc.contributor.googleauthor | Kyong Sik Lee | - |
dc.contributor.googleauthor | Byung Soo Kim | - |
dc.contributor.googleauthor | Jin Ju Kim | - |
dc.identifier.doi | 10.1023/a:1005997421733 | - |
dc.contributor.localId | A01290 | - |
dc.contributor.localId | A01316 | - |
dc.contributor.localId | A02457 | - |
dc.contributor.localId | A03773 | - |
dc.relation.journalcode | J00403 | - |
dc.identifier.eissn | 1573-7217 | - |
dc.identifier.pmid | 9694610 | - |
dc.identifier.url | https://link.springer.com/article/10.1023/a%3A1005997421733 | - |
dc.contributor.alternativeName | Roh, Jae Kyung | - |
dc.contributor.affiliatedAuthor | 노재경 | - |
dc.contributor.affiliatedAuthor | 라선영 | - |
dc.contributor.affiliatedAuthor | 유내춘 | - |
dc.contributor.affiliatedAuthor | 정현철 | - |
dc.citation.volume | 49 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 41 | - |
dc.citation.endPage | 50 | - |
dc.identifier.bibliographicCitation | BREAST CANCER RESEARCH AND TREATMENT, Vol.49(1) : 41-50, 1998 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.